Travecta Therapeutics to Present at Ventures Day

Travecta Therapeutics is one of eight companies that will present at SPRIM’s quarterly Ventures Day meeting in New York on April 24. The event will provide insights into the latest innovations and trends in biotech and digital health.

learn more

Travecta Therapeutics Presents Corporate Updates at TKS 1 Investor Day

February 7, 2019

Travecta Therapeutics, an emerging biotech company utilizing its novel Blood-Brain Barrier (BBB) Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system (CNS), presented its corporate strategy at the second annual TKS 1 Investor Day in Singapore.

learn more

Travecta Therapeutics Appoints Douglas C. Hicks as Chief Business Officer

13 September 2018

Travecta Therapeutics, an emerging biotech company developing a platform that leverages its proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents across the blood-brain barrier, announces it has appointed Douglas C. Hicks as Chief Business Officer. Mr. Hicks will serve on the Travecta Therapeutics executive leadership team and lead business development and corporate strategy for the company.

learn more

Tackling the blood-brain barrier: Duke-NUS discovery leads to startup Travecta

22 March 2018

Travecta Therapeutics Pte Ltd. is the latest startup to join Singapore’s biotech block. The newly formed drug discovery company is based on intellectual property derived from discoveries made at Duke-NUS Medical School (Duke-NUS).

Travecta is based on the findings of its scientific founder, David Silver, who published research in 2014 that established a path and transport system that specifically takes lipids such as the omega-3 fatty acid – docosahexaenoic acid (DHA) – to the brain. Silver discovered that a transporter protein called Mfsd2a carries DHA in the chemical form of lysophosphatidylcholine (LPC) to the brain.

learn more

Duke-NUS commercializes discovery to deliver therapeutics across blood brain barrier

1 March 2018

Intellectual property (IP) derived from discoveries made at Duke-NUS Medical School (Duke-NUS) have been licensed to a newly formed biotech start-up, Travecta Therapeutics Pte Ltd, a Singapore-based drug discovery company. Travecta plans to use the Duke-NUS technology to develop new therapeutic agents that can be selectively delivered across the blood brain barrier for treatment of diseases of the brain, eye and central nervous system.

learn more


The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain

August 2018

Brain acquisition of DHA is primarily mediated by the transporter Major Facilitator Superfamily Domain containing 2a (Mfsd2a) expressed in the endothelium of the blood-brain barrier (BBB) and other abundant cell types within the brain. Mfsd2a transports DHA and other polyunsaturated fatty acids (PUFAs) esterified to lysophosphatidylcholine (LPC-DHA).

learn more

MFSD2A is a transporter for the essential OMEGA-3 fatty acid docosahexaenoic acid.

Nature, 2014. 509(7501): p. 503-6

Here we identify a member of the major facilitator super family—
Mfsd2a (previously an orphan transporter) —as the major transporter for DHA uptake into brain. Mfsd2a is
found to be expressed exclusively in endothelium of the blood–brain barrier of micro-vessels. Importantly,
Mfsd2a-knockout mice have markedly reduced uptake of labelled LPC-DHA, and other LPCs, from plasma into the
brain, demonstrating that Mfsd2a is required for brain uptake of DHA. Our findings reveal an unexpected essential physiological role of plasma-derived LPCs in brain growth and function.

learn more